Clinical effects of rivaroxaban and low molecular weight heparin on acute exacerbation of chronic obstructive pulmonary disease in elderly patients
Zhang Jinchao
Cui Yue'e
Liu Na
Wang Yafang
Jiao Yaping
Cui Zhaobo
Abstract：Objective To analyze the clinical effects of rivaroxaban and low molecular weight heparins (LMWH) on acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in elderly patients.Methods From March 2017 to March 2018,120 elderly patients with AECOPD were enrolled in Harrison International Peace Hospital Affiliated to Hebei Medical University.They were randomly divided into rivaroxaban group and LMWH group,with 60 cases in each group.Both groups had routine treatments including anti-infection,oxygen therapy,ventilation,relieving spasm and asthma,relieving cough and phlegm,improving cardiac function and nutrition.The LMWH group was treated with subcutaneous injection of LMWH and the rivaroxaban group took rivaroxaban tablets on the basis of routine treatments.Therapeutic effect,hospitalization time,blood gas indicators including pH value,arterial oxygen partial pressure (PaQ),arterial carbon dioxide partial pressure (PaCO2),PaO2/inhaled oxygen concentration(FiO2) and adverse reactions were analyzed.Results The total effective rate in rivaroxaban group was significantly higher than that in LMWH group[86.7％ (52/60) vs 61.7％ (37/60)](P ＜0.05).The mean hospitalization time in rivaroxaban group was significantly shorter than that in LMWH group [(11.5 ± 1.4) d vs (17.5 ± 7.1) d] (P ＜ 0.01).There was no significant difference of blood gas indicators between groups before treatment (P ＞ 0.05).After treatment,pH value,PaO2 and PaO2/FiO2 in rivaroxaban group were significantly higher than those in LMWH group[(7.38 ±0.17) vs (7.30 ±0.14),(88 ± 6)mmHg vs (80 ±4)mmHg,(315 ± 16)mmHg vs (240 ± 15)mmHg];PaCO2 in rivaroxaban group was significantly lower than that in LMWH group[(43.5 ± 2.8) mmHg vs (59.2 ± 6.2) mmHg] (P ＜ 0.05).The incidence of adverse reactions in rivaroxaban group was significantly lower than that in LMWH group[3.3％ (2/60) vs 21.7％ (13/60)](P ＜0.05).Conclusion Rivaroxaban shows a better anticoagulant effect on AECOPD in elderly patients than LMWH;the advantages include short hospitalization time,optimistic blood gas condition and few adverse reaction.
Keywords：Acute exacerbation of chronic obstructive pulmonary diseaseLow molecular heparinRivaroxaban
Publication Date：2019-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)
Pages：4( 533-536 )